Cooley Advises Depomed in its $240 Million Diabetes Drug Sale to PDL BioPharma

Palo Alto, Calif. – October 22, 2013 – Cooley LLP announced today that it advised Depomed, Inc. in its sale of interests in royalty and milestone payments in the Type 2 diabetes therapeutic area to PDL BioPharma, Inc. for $240.5 million. Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.

The Cooley team advising Depomed on the sale was led by partners Mischi a Marca and Glen Sato and included partner and head of the firm's medical device practice Mark Weeks; partner Bill Morrow (tax); partners Francis Fryscak and Howard Morse (antitrust); special counsel Marina Remennik; and associates Jason Savich and Rena Kaminsky.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors and established companies. Clients partner with Cooley on transformative deals, complex IP matters and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 700 lawyers across eleven offices in the United States and China.

www.cooley.com

Related Contacts
Bill Morrow Retired Partner, San Diego
Mischi a Marca Partner, San Francisco
Rena Kaminsky Special Counsel, Palo Alto
Jason Savich Partner, San Francisco
Mark Weeks Partner, Palo Alto
Marina Remennik Special Counsel, Palo Alto
Howard Morse Partner, Washington, DC